ArticleFrontiers in oncology2026
Enhanced early detection of thyroid cancer using ensemble machine learning and serum proteomics.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid cancer presents a significant clinical challenge due to asymptomatic onset and poor post-metastasis prognosis. Current imaging methods lack specificity, and single biomarkers show limited diagnostic accuracy. This study aimed to develop and validate a diagnostic model integrating serum proteomics and machine learning for early detection. Methods: Serum samples from 414 thyroid cancer patients and 430 healthy controls were analyzed using MALDI-TOF MS. Multiple machine learning algorithms were applied to construct diagnostic models and evaluated in an independent test set. Model interpretability was assessed using SHAP and LIME, and key peptide were identified through feature importance analysis. A simplified diagnostic model was subsequently reconstructed using the selected features. Discriminative performance was evaluated using ROC-AUC and DCA. GO and KEGG enrichment analyses were performed to elucidate the biological functions of differentially expressed proteins. Results: The integrated machine learning model demonstrated excellent discriminative performance. Interpretability analyses indicated that the high performance of the model was driven by the robust and coordinated contributions of multiple features. 12 peptide peaks significantly associated with thyroid cancer were identified, and the simplified model based on these features maintained high diagnostic accuracy and provided greater net clinical benefit than single-protein biomarkers. Enrichment analysis revealed that those proteins were involved in immune regulation, lipid metabolism, and other cancer-related biological processes. Conclusions: This study established and validated a serum peptide-based diagnostic model integrating machine learning for thyroid cancer, exhibiting promising diagnostic performance in the single-center cohort, providing a non-invasive strategy for early detection and a basis for further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.